Gal-3 expression in human pancreatic tumor tissues.

<p>A, Tissue microarray slides consisting of 125 pancreatic ductal adenocarcinomas and paired non-neoplastic pancreatic tissue samples were immunohistochemically stained using a monoclonal Gal-3 antibody as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0042699#s2" target="_blank">Materials and Methods</a>. Gal-3 expression was increased along the disease sequence-normal (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0042699#pone-0042699-g001" target="_blank">Figure 1A, a,b</a>), pancreatitis (c,d) and pancreatic ductal adenocarcinoma (e,f). B. Summary of Gal-3 IHC of the PDAC tissue microarrays. The tumors were categorized into Gal3-low (combined scores ≤3) and Gal3-high (combined score ≥4) based on the percentage of Gal-3 staining in tumor cells (0, no staining; 1, ≤10%; 2, 10–50% and 3, >50%) and the staining intensity (0-negative, 1-weak, 2-moderate and 3- strong).